Similar articles

• Improving the outlook for myelodysplastic syndrome.

  Brower V. Brower V. J Natl Cancer Inst. 2012 Aug 22;104(16):1204-6. doi: 10.1093/jnci/djs368. Epub 2012 Aug 16. J Natl Cancer Inst. 2012. PMID: 22899627 No abstract available.
• Myelodysplastic syndromes (MDS).

  Klimek V. Klimek V. Best Pract Res Clin Haematol. 2015 Mar;28(1):1-2. doi: 10.1016/j.beha.2014.11.007. Epub 2014 Nov 29. Best Pract Res Clin Haematol. 2015. PMID: 25659724 No abstract available.
• New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.

  Loiseau C, Ali A, Itzykson R. Loiseau C, et al. Exp Hematol. 2015 Aug;43(8):661-72. doi: 10.1016/j.exphem.2015.05.014. Epub 2015 Jun 27. Exp Hematol. 2015. PMID: 26123365 Review.
• New agents in the treatment of MDS.

  List AF. List AF. Clin Adv Hematol Oncol. 2005 Nov;3(11):832-4. Clin Adv Hematol Oncol. 2005. PMID: 16491623 No abstract available.
• [Epigenetic therapy in myelodysplastic syndromes].

  Maki K, Mitani K. Maki K, et al. Rinsho Ketsueki. 2011 Jul;52(7):438-46. Rinsho Ketsueki. 2011. PMID: 21821974 Review. Japanese. No abstract available.